Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Dabigatran has been demonstrated to decrease the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) by one-third, while also decreasing the rate of intracranial bleeding by two-thirds compared with warfarin.

Effect of Dabigatran on Referrals to and Switching from Warfarin